Related Experiment Video
Updated: Apr 22, 2026
07:40
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.8K
Chemotherapy induced Takotsubo cardiomyopathy
Sunny Goel1, Abhishek Sharma1, Aakash Garg1
1Sunny Goel, Abhishek Sharma, Abhinav Chandra, Vijay Shetty, Department of Medicine, Maimonides Medical Center, Brooklyn, NY 11219, United States.
World Journal of Clinical Cases
|October 18, 2014
Summary
This report details the first known case of Takotsubo cardiomyopathy, a heart condition, linked to the chemotherapy drugs daunorubicin and cytarabine in a patient with acute myeloid leukemia.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Chemotherapy-induced Takotsubo cardiomyopathy (TTC) is a recognized complication.
- Literature primarily focuses on 5-fluorouracil as a causative agent.
- Acute myeloid leukemia (AML) treatment often involves intensive chemotherapy regimens.
Observation:
- A 55-year-old Asian male diagnosed with AML received combination chemotherapy.
- The patient developed symptoms consistent with Takotsubo cardiomyopathy during treatment.
- Cardiac evaluation confirmed the diagnosis of TTC.
Findings:
- This case represents the first documented instance of TTC associated with daunorubicin and cytarabine.
- The patient's cardiac dysfunction resolved after chemotherapy cessation.
- This suggests a potential direct cardiotoxic effect of these specific AML chemotherapeutic agents.
Implications:
- Highlights the need for increased awareness of TTC in AML patients undergoing daunorubicin/cytarabine therapy.
- Suggests cardiac monitoring protocols may need adjustment for patients receiving these drugs.
- Further research is warranted to elucidate the mechanisms of daunorubicin/cytarabine-induced cardiotoxicity.
Related Concept Videos
01:14Myocarditis III: Medical Management
340
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
340
01:25Cardiomyopathy I: Introduction and Classification
806
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
806
01:26Heart Failure Drugs: Inotropic Agents
1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
01:22Myocarditis IV: Nursing Management
385
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
385
01:30Cardiomyopathy II: Dilated Cardiomyopathy
766
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
766
01:29Cardiomyopathy V: Interprofessional Care
742
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
742